Implantable devices/implantation therapy controlled release potential

The development of polymeric drug delivery devices for sustained ophthalmic CsA release is an active area of research for uveitis, vitreous inflammation, dry eye, and prevention of cornea transplant rejection. The use of these specialized CsA-delivering ophthalmic systems (e.g., implants nanoparticle and microsphere injections) cannot be completely reviewed in this chapter and readers are referred to an alternative text. A sample of applicable polymers for delivery of CsA for uveitis and vitreous inflammation is offered in the accompanying table (Table 15.4). The treatment of posterior uveitis and vitreous inflammation usually involves chronic therapy (often years) of topical agents and frequent intravitreal injections for disease control. These therapies are often impractical and subject to medical non-adherence [33]. Polymeric implants or injectable polymer sustained release systems can potentially improve patient outcomes through optimized intraocular drug concentrations. 

---